SCHEMBL21497367

SCHEMBL21497367

CC(C)(F)c1ccc(C(C)(F)F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.39
TSHR P16473 3/20 0.35
PDE2A O00408 2/20 0.33
ESR1 P03372 2/20 0.33
ESR2 Q92731 2/20 0.33
LMNA P02545 1/20 0.33
TYR P14679 1/20 0.33
CYP3A4 P08684 1/20 0.33
AR P10275 1/20 0.33
HPGD P15428 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
HTR6 P50406 1/20 0.33
ESRRG P62508 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NR1H2 P55055 2/20 0.32
NR1H3 Q13133 2/20 0.32
KIF11 P52732 3/20 0.31
PTPN11 Q06124 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12299036 0.90 TSHR (0.40) TSHRPDE2AESR1ESR2LMNA
SCHEMBL497773 0.90 HSD11B1 (0.43) HSD11B1TSHRPDE2AESR1ESR2
SCHEMBL14703793 0.81 ALDH1A1 (0.50) TSHRKIF11ALDH1A1
SCHEMBL12024885 0.81 TSHR (0.55) TSHRLMNATYRHPGDHSD17B10
SCHEMBL16277011 0.81 TSHR (0.55) HSD11B1TSHRLMNATYRHPGD
SCHEMBL14703788 0.79 HSD11B1 (0.44) HSD11B1CYP3A4MEN1KMT2AALDH1A1
SCHEMBL8015827 0.79 TSHR (0.60) TSHRKIF11ALDH1A1CA1CA2
SCHEMBL15280394 0.79 TSHR (0.60) HSD11B1TSHRKIF11ALDH1A1CA1
SCHEMBL23116738 0.77 MEN1 (0.56) TSHRLMNASLC6A2SLC6A4SLC6A3
SCHEMBL1085590 0.77 CA1 (0.46) HSD11B1KIF11MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450286-B2 Compounds and compositions for inhibition of FASN FORMA THERAPEUTICS, INC. (US) 2019-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450286-B2 Compounds and compositions for inhibition of FASN FASN, FABP1, SCD HSD11B1 489/4885TSHR 3610/4885PDE2A 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.